NCT03508570
- Conditions
- Abdominal Neoplasms, Adnexal Diseases, Digestive System Diseases, +58 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Clinical trial condition
Platinum-Refractory Primary Peritoneal Carcinoma
Explore clinical trials studying Platinum-Refractory Primary Peritoneal Carcinoma. Study availability and eligibility vary by location and protocol.
3 public trials
0 recruiting studies
Platinum-Refractory Primary Peritoneal Carcinoma trial results
Active, Not Recruiting
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
NCT04739800
- Conditions
- Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, +47 more
- Locations
-
- Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
- Anchorage Radiation Therapy Center Anchorage, Alaska, United States
- Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
- Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
Active, Not Recruiting
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
NCT05271318
- Conditions
- Adenoviridae Infections, DNA Virus Infections, Infections, +10 more
- Locations
-
- Mayo Clinic Rochester, Minnesota, United States
- Northwell Heatlh/Lenox Hill Hospital New York, United States
- Docrates Cancer Center Helsinki, Finland